Literature DB >> 25975642

Synthetic 1,2,3-triazole-linked glycoconjugates bind with high affinity to human galectin-3.

Marcelo Fiori Marchiori1, Dênio Emanuel Pires Souto2, Leandro Oliveira Bortot1, João Francisco Pereira1, Lauro Tatsuo Kubota2, Richard D Cummings3, Marcelo Dias-Baruffi1, Ivone Carvalho1, Vanessa Leiria Campo4.   

Abstract

This work describes the synthesis of the 1,2,3-triazole amino acid-derived-3-O-galactosides 1-6 and the 1,2,3-triazole di-lactose-derived glycoconjugate 7 as potential galectin-3 inhibitors. The target compounds were synthesized by Cu(I)-catalyzed azide-alkyne cycloaddition reaction ('click chemistry') between the azido-derived amino acids N3-ThrOBn, N3-PheOBn, N3-N-Boc-TrpOBn, N3-N-Boc-LysOBn, N3-O-tBu-AspOBn and N3-l-TyrOH, and the corresponding alkyne-based sugar 3-O-propynyl-GalOMe, as well as by click chemistry reaction between the azido-lactose and 2-propynyl lactose. Surface plasmon resonance (SPR) assays showed that all synthetic glycoconjugates 1-7 bound to galectin-3 with high affinity, but the highest binders were the amino acids-derived glycoconjugates 2 (KD 7.96μM) and 4 (KD 4.56μM), and the divalent lactoside 7 (KD1 0.15μM/KD2 19μM). Molecular modeling results were in agreement with SPR assays, since more stable interactions with galectin-3 were identified for glycoconjugates 2, 4 and 7. Regarding compounds 2 and 4, they established specific cation-π (Arg144) and ionic (Asp148) interactions, whereas glycoconjugate 7 was capable to bridge two independent galectin-3 CRDs, creating a non-covalent cross-link between two monomers and, thus, reaching a submicromolar affinity towards galectin-3.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Galectin-3; Glycoconjugates; Molecular modeling; Surface plasmon resonance; Triazole; ‘Click chemistry’

Mesh:

Substances:

Year:  2015        PMID: 25975642     DOI: 10.1016/j.bmc.2015.04.044

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

1.  Effects of linker and liposome anchoring on lactose-functionalized glycomacromolecules as multivalent ligands for binding galectin-3.

Authors:  Tanja Freichel; Dominic Laaf; Miriam Hoffmann; Patrick B Konietzny; Viktoria Heine; Robert Wawrzinek; Christoph Rademacher; Nicole L Snyder; Lothar Elling; Laura Hartmann
Journal:  RSC Adv       Date:  2019-07-29       Impact factor: 4.036

Review 2.  Synthetic glycoconjugates inhibitors of tumor-related galectin-3: an update.

Authors:  Vanessa Leiria Campo; Marcelo Fiori Marchiori; Lílian Cataldi Rodrigues; Marcelo Dias-Baruffi
Journal:  Glycoconj J       Date:  2016-08-15       Impact factor: 2.916

3.  Biotinylated N-Acetyllactosamine- and N,N-Diacetyllactosamine-Based Oligosaccharides as Novel Ligands for Human Galectin-3.

Authors:  Sophia Böcker; Lothar Elling
Journal:  Bioengineering (Basel)       Date:  2017-04-05

4.  Design, Synthesis, and Anticancer Activity of a Selenium-Containing Galectin-3 and Galectin-9N Inhibitor.

Authors:  Sonia Di Gaetano; Luciano Pirone; Ioannis Galdadas; Serena Traboni; Alfonso Iadonisi; Emilia Pedone; Michele Saviano; Francesco Luigi Gervasio; Domenica Capasso
Journal:  Int J Mol Sci       Date:  2022-02-25       Impact factor: 5.923

5.  Understanding the role of galectin inhibitors as potential candidates for SARS-CoV-2 spike protein: in silico studies.

Authors:  Aaftaab Sethi; Swetha Sanam; Sharon Munagalasetty; Sivaraman Jayanthi; Mallika Alvala
Journal:  RSC Adv       Date:  2020-08-13       Impact factor: 4.036

6.  Thiodigalactoside-Bovine Serum Albumin Conjugates as High-Potency Inhibitors of Galectin-3: An Outstanding Example of Multivalent Presentation of Small Molecule Inhibitors.

Authors:  Hao Zhang; Dominic Laaf; Lothar Elling; Roland J Pieters
Journal:  Bioconjug Chem       Date:  2018-03-07       Impact factor: 4.774

7.  Synthesis and evaluation of porphyrin glycoconjugates varying in linker length: preliminary effects on the photodynamic inactivation of Mycobacterium smegmatis.

Authors:  Charlie F Dixon; Ana N Nottingham; Ana Frances Lozano; J Alexander Sizemore; Logan A Russell; Chelsea Valiton; Kimberly L Newell; Dominique Babin; William T Bridges; Matthew R Parris; David V Shchirov; Nicole L Snyder; Joshua V Ruppel
Journal:  RSC Adv       Date:  2021-02-10       Impact factor: 3.361

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.